Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%



Code Company Date Close Change Indicator Value Signal

Trading Performance

Average True Range



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 5 108.6 0.60% 1.50% 51.4% -13.8% 126.8%
SHORT 4 38.8 0.25% 0.33% 28.6% -31.5% -65.9%


Technical Analysis

Ra Pharmaceuticals Inc has a TR of 0.14, and an ATR(14) of 0.21.

Average true range (ATR) is a technical analysis volatility indicator originally developed by J. Welles Wilder Jr. for commodities. The indicator does not provide an indication of price trend simply the degree of price volatility.

Calculation: Average True Range (ATR):
1) Current ATR = [(Prior ATR x 13) + Current TR] / 14;
2) Where TR = max[(high-low) abs(high-close previous) abs (low-close previous)]

PROFILE: Ra Pharmaceuticals Inc (RARX)

Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Average True Range

Company Close Change(%) Volume Value Signal
ARAY Accuray Incorporated 3.95 7.9 2,162,586 0.21 NEUTRAL
GBLI Global Indemnity Plc 32.56 6 9,228 0.86 NEUTRAL
TLGT Teligent 0.42 5.5 1,235,129 0.05 NEUTRAL
ADRO Aduro Biotech 1.48 5 1,056,005 0.1 NEUTRAL
SYRS Syros Pharmaceuticals 8.2 4.9 153,243 0.61 NEUTRAL
XENT Intersect Ent 25.17 4.7 1,131,415 1.14 NEUTRAL
MGI Moneygram 2.68 4.7 2,612,033 0.21 NEUTRAL
FARM Farmer Brothers 13.38 4.4 116,584 0.52 NEUTRAL
TRUP Trupanion Inc 33.32 4.2 261,897 1.34 NEUTRAL
MESO Mesoblast Ads 9.99 4.1 130,699 0.46 NEUTRAL